Comparison

Anti-Human Nerve Growth Factor (Tanezumab) - 100 mg

Item no. LEIN-T824-100mg
Manufacturer Leinco Technologies
Amount 100 mg
Quantity options 1 mg 100 mg 25 mg 50 mg 5 mg
Category
Type Antibody Monoclonal
Applications FA, other
Clone RN624
Specific against other
ECLASS 10.1 42030590
ECLASS 11.0 42030590
UNSPSC 12352203
Shipping Condition Cool pack
Available
Manufacturer - Applications
B, FA
Manufacturer - Category
All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies
Manufacturer - Targets
Beta-Nerve Growth Factor
Shipping Temperature
2 - 8°C Wet Ice
Storage Conditions
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Product Description
Nerve growth factor (NGF) is a neurotrophin that regulates the structure and function of responsive sensory neurons1. In particular, NGF is involved in the transmission and sensation of inflammatory and neuropathic pain2. NGF is elevated in patients with arthritis, pancreatitis, and prostatitis as well as in animal models of inflammatory pain3. Additionally, increased expression of NGF in injured or inflamed tissue is associated with increased pain while blocking NGF in animal models reduces signs of pain. Therefore, harnessing NGF for pain modulation via therapeutic antagonism is of interest for inflammatory disease management. An antibody-based analgesic would also potentially avoid the gastrointestinal and cardiorenal side effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and narcotics typically used for pain management and may also help avoid or delay surgical intervention. Tanezumab is a humanized and affinity matured form of antibody clone E34 that blocks the interaction between NGF and its receptors TrkA and p751. Tanezumab/NGF binding is extremely stable, with dissociation too slow to detect in both surface- and solution-based assays2. Kinetics assays show that NGF binds as one whole homodimer to one tanezumab arm2. An NGF dimer “half-saturated” with a single molecule of tanezumab can use its second subunit to bind either a second molecule of tanezumab or simultaneously bind TrkA or p75 in addition to tanezumab. Tanezumab significantly reduces knee pain, stiffness, and limitations of physical function in patients with osteoarthritis3 and may have some therapeutic effect on lower back pain 11.
Manufacturer - Research Area
Biosimilars, Immunology, Inflammatory Disease, Neuroscience, Osteoarthritis
Concentration
≥ 5.0 mg/ml
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Antigen Distribution
Nerve growth factor is produced by a number of cell types including mastcells, B lymphocytes, keratinocytes, smooth muscle cells, fibroblasts, bronchial epithelial cells, renal mesangial cells, and skeletal muscle myotubes. Nerve growth factor expression is increasedin inflamed tissues.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close